Prestige Wealth Management Group’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
Other funds holding TXG
AIM
SIM
GIM
BCM
Prestige Wealth Management Group's TXG Position: Q2 2022 in Review
Prestige Wealth Management Group sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 13 shares — an estimated $1K sold.
Prestige Wealth Management Group first reported a position in TXG in Q1 2020 and held it in 9 quarters. The position peaked at $9K in Q2 2021. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.
- Prestige Wealth Management Group reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
- Prestige Wealth Management Group sold 13 10x Genomics shares in Q2 2022, an estimated $1K.
- Prestige Wealth Management Group first reported a position in 10x Genomics in Q1 2020 and held it in 9 quarters.
- Prestige Wealth Management Group's 10x Genomics position peaked at $9K in Q2 2021.
- 254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.
Based on Prestige Wealth Management Group's 13F filing for Q2 2022, filed 10 Aug 2022.